Skip to main content

Delayed Graft Function clinical trials at UC Davis
1 research study open to eligible people

  • A Study of Experimental Medicine BB3 to Reduce the Severity of Delayed Graft Function (DGF) in Kidney Transplants

    open to eligible people ages 18 years and up

    A Multicenter, Prospective, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study of BB3 to Reduce the Severity of Delayed Graft Function in Recipients of a Deceased Donor Kidney. The major objective is to demonstrate the safety and efficacy of BB3 in reducing the severity of delayed graft function (DGF) in recipients at high risk of DGF after receiving a deceased donor renal allograft.

    Los Angeles, California and other locations